Tourmaline Bio (TRML) Stock Forecast, Price Target & Predictions
TRML Stock Forecast
Tourmaline Bio stock forecast is as follows: an average price target of $65.33 (represents a 178.00% upside from TRML’s last price of $23.50) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
TRML Price Target
The average price target for Tourmaline Bio (TRML) is $65.33 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $74.00 to $50.00. This represents a potential 178.00% upside from TRML's last price of $23.50.
TRML Analyst Ratings
According to 3 Wall Street analysts, Tourmaline Bio's rating consensus is 'Buy'. The analyst rating breakdown for TRML stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Tourmaline Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 21, 2024 | Yatin Suneja | Guggenheim | $50.00 | $28.61 | 74.76% | 112.77% |
| Mar 20, 2024 | Robyn Karnauskas | Truist Financial | $74.00 | $44.67 | 65.66% | 214.89% |
| Mar 20, 2024 | Roger Song | Jefferies | $72.00 | $44.67 | 61.18% | 206.38% |
The latest Tourmaline Bio stock forecast, released on Mar 21, 2024 by Yatin Suneja from Guggenheim, set a price target of $50.00, which represents a 74.76% increase from the stock price at the time of the forecast ($28.61), and a 112.77% increase from TRML last price ($23.50).
Tourmaline Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $65.33 |
| Last Closing Price | $23.50 | $23.50 | $23.50 |
| Upside/Downside | -100.00% | -100.00% | 178.00% |
In the current month, the average price target of Tourmaline Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Tourmaline Bio's last price of $23.50. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 04, 2024 | Guggenheim | Buy | Buy | Hold |
| Oct 15, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| Sep 04, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Tourmaline Bio's last stock rating was published by Guggenheim on Nov 04, 2024. The company gave TRML a "Buy" rating, the same as its previous rate.
Tourmaline Bio Financial Forecast
Tourmaline Bio Revenue Forecast
| Revenue |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| # Analysts |
| Surprise % |
Tourmaline Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TRML's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Tourmaline Bio EBITDA Forecast
| # Analysts |
| EBITDA |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
undefined analysts predict TRML's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Tourmaline Bio's previous annual EBITDA (undefined) of $NaN.
Tourmaline Bio Net Income Forecast
| # Analysts |
| Net Income |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
Tourmaline Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TRML's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Tourmaline Bio SG&A Forecast
| # Analysts |
| SG&A |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
Tourmaline Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to TRML last annual SG&A of $NaN (undefined).
Tourmaline Bio EPS Forecast
| # Analysts |
| EPS |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
According to undefined Wall Street analysts, Tourmaline Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TRML previous annual EPS of $NaN (undefined).